Zymeworks Inc. Shareholder Meeting Results Announced
Ticker: ZYME · Form: 8-K · Filed: Dec 11, 2024 · CIK: 1937653
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, auditor-appointment
TL;DR
Zymeworks shareholders re-elected directors and approved auditor & exec pay.
AI Summary
On December 10, 2024, Zymeworks Inc. announced the results of its annual general meeting of shareholders. Shareholders voted to elect the nominated directors, approve the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024, and approve an advisory resolution on the compensation of the company's named executive officers.
Why It Matters
The shareholder meeting results confirm the board of directors and auditor, providing stability and regulatory compliance for Zymeworks Inc.
Risk Assessment
Risk Level: low — This filing reports routine shareholder meeting outcomes, which typically carry low risk.
Key Players & Entities
- Zymeworks Inc. (company) — Registrant
- PricewaterhouseCoopers LLP (company) — Independent registered public accounting firm
- December 10, 2024 (date) — Date of earliest event reported
- December 31, 2024 (date) — Fiscal year end
FAQ
What was the date of Zymeworks Inc.'s annual general meeting of shareholders?
The earliest event reported in the filing was on December 10, 2024.
Who was appointed as Zymeworks Inc.'s independent registered public accounting firm?
PricewaterhouseCoopers LLP was approved for appointment.
For which fiscal year was PricewaterhouseCoopers LLP appointed as auditor?
They were appointed for the fiscal year ending December 31, 2024.
What advisory resolution was approved by shareholders regarding executive compensation?
Shareholders approved an advisory resolution on the compensation of the company's named executive officers.
What is Zymeworks Inc.'s state of incorporation?
Zymeworks Inc. is incorporated in Delaware.
Filing Stats: 1,386 words · 6 min read · ~5 pages · Grade level 13.6 · Accepted 2024-12-11 16:05:17
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share ZYME The Nasdaq Stock Mar
- $6,000 — opment committee will be increased from $6,000 to $7,500 with all other annual cash re
- $7,500 — mittee will be increased from $6,000 to $7,500 with all other annual cash retainers fo
Filing Documents
- d903989d8k.htm (8-K) — 58KB
- 0001193125-24-275534.txt ( ) — 176KB
- zyme-20241210.xsd (EX-101.SCH) — 2KB
- zyme-20241210_lab.xml (EX-101.LAB) — 17KB
- zyme-20241210_pre.xml (EX-101.PRE) — 11KB
- d903989d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ZYMEWORKS INC. (Registrant) Date: December 11, 2024 By: /s/ Kenneth Galbraith Name: Title: Kenneth Galbraith Chair of the Board of Directors, President and Chief Executive Officer 4